Antaros Medical was pleased to be invited to share an industry perspective on imaging in multi-organ clinical trials at this year’s MOSAiC Forum.
Although interconnected, chronic liver diseases such as metabolic dysfunction-associated steatohepatitis (MASH) follow distinct trajectories and progression patterns compared to other metabolic conditions like heart failure or chronic kidney disease (CKD). This makes it essential to carefully select the right patient population and apply appropriate biomarkers and endpoints when incorporating imaging sub-studies for cardiac, renal, or other metabolic diseases into MASLD/MASH trials.
Lars Johansson, Chief Scientific Officer at Antaros Medical, addressed this complexity during the session “Changing Paradigm: New Data and Remaining Gaps in Imaging Knowledge.” He highlighted the potential of imaging to provide a holistic view of drug effects across organs, and joined fellow experts in discussing how imaging can help answer key questions in multi-organ drug development.
About MOSAiC
MOSAiC is a global NASH/MASH trialist forum that brings together cardiology, endocrinology, and hepatology clinical trialists with industry, regulatory experts, payers, patient representatives and other stakeholders to further advance collective intelligence and foster collaboration about clinical trials through cross-talks.
This year the MOSAiC forum took place from October 23-24 at the French Embassy in Washington D.C.